Patient Reported Outcomes Poised For Takeoff After Final FDA Guidance
Executive Summary
Companies developing patient-reported outcome measuring tools for drug developers are hoping for a new surge in interest in the wake of FDA's publication of final guidance in December - the culmination of more than a decade of work
You may also be interested in...
Biomarkers, PRO Tools Warrant Separate Qualification Guidelines, Groups Tell FDA
FDA’s midstream decision to expand a biomarker qualification draft guidance to include patient-reported outcome tools has perplexed pharma stakeholders, which seem to think the agency would have been better off leaving well enough, and PROs, alone.
Biomarkers, PRO Tools Warrant Separate Qualification Guidelines, Groups Tell FDA
FDA’s midstream decision to expand a biomarker qualification draft guidance to include patient-reported outcome tools has perplexed pharma stakeholders, which seem to think the agency would have been better off leaving well enough, and PROs, alone.
Cystic Fibrosis Trial Endpoints May Be Revised Following FDA Workshop
Quality-of-life metrics deserve consideration in addition to lung function in the development of aerosolized antimicrobials, researchers say.